Losartan hydroxylation phenotype in an Ecuadorian population: Influence of CYP2C9 genetic polymorphism, habits and gender

Pharmacogenomics

Volumn 13, Issue 15, 2012, Pages 1711-1717

  Dorado, Pedro ^a   Beltrán, Leonardo J ^b   MacHín, Esther ^a   Peñas Lledó, Eva M ^a   Terán, Enrique ^b,c   Llerena, Adrián ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

^c UNIVERSIDAD SAN FRANCISCO DE QUITO   (Ecuador)

Author keywords

CYP2C9 genotype; CYP2C9 hydroxylation; Ecuadorians; Hispanics; losartan

Indexed keywords

CAFFEINE; CYTOCHROME P450 2C; LOSARTAN;

ADULT; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; DOSE RESPONSE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG USE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; SEX DIFFERENCE; SINGLE DRUG DOSE;

ADULT; ALCOHOL DRINKING; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; COFFEE; FEMALE; GENOTYPE; HABITS; HISPANIC AMERICANS; HUMANS; HYDROXYLATION; LOSARTAN; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; SEX FACTORS; SMOKING; YOUNG ADULT;

NICOTIANA TABACUM;

EID: 84870042059     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.160     Document Type: Article

References (30)

1. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525-538 (1998). (Pubitemid 28270907)
2. Yasar U, Forslund-Bergengren C, Tybring G et al. Pharmacokinetics of losartan and its metabolite E3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 71, 89-98 (2002). (Pubitemid 34124042)
3. Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, Llerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 59, 221-225 (2003). (Pubitemid 37009744)
4. Llerena A, Dorado P, Berecz R, González AP, Peñas- Lledó EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur. J. Clin. Pharmacol. 59, 869-873 (2004). (Pubitemid 38337438)
5. Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45, 205-251 (1993). (Pubitemid 23191415)
6. Stearns R A, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 23, 207-215 (1995).
7. Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab. Dispos. 23, 285-289 (1995).
8. Yasar U, Tybring G, Hidestrand M et al. The role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 29, 1051-1056 (2001). (Pubitemid 32605922)
9. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J. Clin. Pharmacol. 43, 84-91 (2003). (Pubitemid 36015447)
10. Caraco Y, Muszkat M, Wood AJ. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11, 587-596 (2001). (Pubitemid 32953584)
11. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J. Clin. Pharmacol. 41, 715-722 (2001). (Pubitemid 32612434)
12. Vesell ES. Genetic and environmental factors affecting drug disposition in man. Clin. Pharmacol. Ther. 22, 659-679 (1977). (Pubitemid 8227787)
13. Wilson K. Sex-related differences in drug disposition in man. Clin. Pharmacokinet. 9, 189-202 (1984). (Pubitemid 14149062)
14. LLerena A, Cobaleda J, Martínez C, Benítez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur. J. Drug Metab. Pharmacokinet. 21, 129-138 (1996). (Pubitemid 26246156)
15. Tatsumi A, Ikegami Y, Morii R, Sugiyama M, Kadobayashi M, Iwakawa S. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1. Biol. Pharm. Bull. 32, 517-519 (2009).
16. Mwinyi J, Cavaco I, Yurdakok B, Mkrtchian S, Ingelman-Sundberg M. The ligands of estrogen receptor a regulate cytochrome P4502C9 (CYP2C9) expression. J. Pharmacol. Exp. Ther. 338, 302-309 (2011).
17. LLerena A, Dorado P, Peñas-LLedó EM. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10, 17-28 (2009).
18. Okin PM, Kjeldsen SE, Dahlöf B, Devereux RB. Racial differences in incident heart failure during antihypertensive therapy. Circ. Cardiovasc. Qual. Outcomes 4, 157-164 (2011).
19. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355 (2001). (Pubitemid 32939439)
20. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene Eur. J. Clin. Invest. 33, 23-30 (2003).
21. Dorado P, Machín E, de Andrés F, González- Naranjo ME, Peñas-LLedó EM, LLerena A. Development of a new HPLC method for the determination of losartan urinary metabolic ratio and its relation to CYP2C9 genotypes. Drug Metab. Drug Interact. (2012) (In Press).
22. Imai J, Ieiri I, Mamiya K et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10, 85-89 (2000). (Pubitemid 30142817)
23. Yasar U, Aklillu E, Canaparo R et al. Analysis of CYP2C9 5 in Caucasian, Oriental and black-African populations. Eur. J. Clin. Pharmacol. 58, 555-558 (2002). (Pubitemid 35435508)
24. Babaoglu MO, Yasar U, Sandberg M et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur. J. Clin. Pharmacol. 60, 337-342 (2004). (Pubitemid 39066253)
25. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab. Dispos. 32, 484-489 (2004). (Pubitemid 38535025)
26. Laine K, Yasar U, Widén J, Tybring G. A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol. Toxicol. 93, 77-81 (2003). (Pubitemid 36981412)
27. LLerena A, Dorado P, O'Kirwan F, Jepson R, Licinio J, Wong ML. Lower frequency of CYP2C9 2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J. 4, 403-406 (2004). (Pubitemid 39600058)
28. Dorado P, Sosa-Macias MG, Peñas-LLedó EM et al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J. 11, 108-112 (2011).
29. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 76, 18-26 (2004). (Pubitemid 38844730)
30. Bravo-Villalta HV, Yamamoto K, Nakamura K, Bayá A, Okada Y, Horiuchi R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur. J. Clin. Pharmacol. 61, 179-184 (2005). (Pubitemid 40768549)